Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 25, 2025 20:06 ET | Source: Skye Bioscience, Inc.

Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, April 25, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic...
April 15, 2025 07:00 ET | Source: Skye Bioscience, Inc.

Skye Bioscience Demonstrates Over 30% Weight Loss with Nimacimab and Tirzepatide Combination in Preclinical Model

Nimacimab shows comparable weight loss to monlunabant and tirzepatide alone, and an additive effect in combination with tirzepatide, in diet-induced obesity modelNew in vitro data demonstrates...
April 14, 2025 07:00 ET | Source: Skye Bioscience, Inc.

Skye Bioscience to Conduct Meetings at Piper Sandler Conference

SAN DIEGO, April 14, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for obesity and...
March 20, 2025 16:01 ET | Source: Skye Bioscience, Inc.

Skye Bioscience Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Enrollment completed in Phase 2a CBeyond™ trial of CB1 inhibitor, nimacimab, in obesity and overweightFaster-than-expected enrollment enables full top-line Phase 2a data in late Q3/early Q4 2025,...
March 14, 2025 07:00 ET | Source: Skye Bioscience, Inc.

Skye Bioscience to Announce 2024 Financial Results on March 20th, 2025

SAN DIEGO, March 14, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and...
February 27, 2025 18:00 ET | Source: Skye Bioscience, Inc.

Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic...
February 24, 2025 07:00 ET | Source: Skye Bioscience, Inc.

Skye Bioscience to Participate in SXSW Session on Obesity

SAN DIEGO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for obesity and...
February 20, 2025 07:00 ET | Source: Skye Bioscience, Inc.

Skye Bioscience to Present at TD Cowen Health Care Conference

SAN DIEGO, Calif., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for...
February 04, 2025 07:00 ET | Source: Skye Bioscience, Inc.

Skye Bioscience Announces Participation in February Conferences

SAN DIEGO, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for obesity and...
January 13, 2025 07:00 ET | Source: Skye Bioscience, Inc.

Skye Bioscience Provides 2025 Look Ahead and Year in Review

SAN DIEGO, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company developing new therapeutic pathways for metabolic health,...